- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.01. | Elevation Oncology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| ELEVATION ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 13.01. | Elevation Oncology advances gastric cancer trial, eyes new data in 2025 | 2 | Investing.com | ||
| 13.01. | Elevation Oncology erzielt Fortschritte bei Magenkrebs-Studie und plant neue Daten für 2025 | 2 | Investing.com Deutsch | ||
| 13.01. | Elevation Oncology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.01. | Elevation Oncology: Promising Cancer Therapies Earn Analyst Praise | 2 | Benzinga.com | ||
| 12.12.24 | Elevation Oncology wählt EO-1022 als HER3-ADC-Kandidaten aus | 1 | Investing.com Deutsch | ||
| 12.12.24 | Elevation Oncology selects EO-1022 as HER3 ADC candidate | 4 | Investing.com | ||
| 12.12.24 | Synaffix B.V.: Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline Expansion | 329 | PR Newswire | Licensing agreement gives Elevation Oncology access to Synaffix's ADC technology for one program in combination with SYNstatin EElevation Oncology nominates a novel HER3 ADC candidate EO-1022... ► Artikel lesen | |
| 05.12.24 | Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024 | 66 | PR Newswire | -- Treatment with both combination regimens demonstrates synergistic anti-tumor activity, supporting planned combination strategy for EO-3021 in patients with gastric... ► Artikel lesen | |
| 13.11.24 | NEC Corporation: Predictive Heart Monitoring Startup, GPx, Secures New Investment From NEC X; Joins Elev X! Boost Venture Studio Program | 537 | JCN Newswire | New Implant and Needle-Free Solution, CardioID, Uses AI and ML to Surpass Accuracy of Conventional Heart MonitoringPALO ALTO, CA, Nov 13, 2024 - (JCN Newswire) - NEC X, the Silicon Valley venture studio... ► Artikel lesen | |
| 06.11.24 | Elevation Oncology GAAP EPS of -$0.22 misses by $0.02 | 1 | Seeking Alpha | ||
| 06.11.24 | Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements | 145 | PR Newswire | -- Promising initial Phase 1 data of EO-3021 reported in August highlighting 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer... ► Artikel lesen | |
| 06.11.24 | Elevation Oncology, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 06.11.24 | Elevation Oncology, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 16.10.24 | NEC X Unveils Elev X! Ignite Cohort Batch 12 | 2 | pulse2.com | ||
| 24.09.24 | FDA grants fast track designation for Elevation Oncology's EO-3021 | 1 | Pharmaceutical Business Review | ||
| 23.09.24 | Elevation Oncology Receives Fast Track Designation For EO-3021 | 1 | RTTNews | ||
| 23.09.24 | FDA grants fast track to Elevation Oncology's cancer drug | 1 | Investing.com | ||
| 23.09.24 | FDA erteilt Elevation Oncology's Krebsmedikament Fast-Track-Status | 1 | Investing.com Deutsch | ||
| 23.09.24 | Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2 | 83 | PR Newswire | BOSTON, Sept. 23, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients... ► Artikel lesen |
Seite:
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MODERNA | 28,735 | -2,48 % | Moderna: Gegenwind aus der Politik | Die Aktie von Moderna gehört heute zu den größeren Verlierern an der Wall Street. Der Grund: US-Behörden wollen einen 590-Millionen-Dollar-Vertrag überprüfen, den das Unternehmen kurz vor dem Ende von... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,831 | +0,97 % | Palatin Technologies Inc. Q2 Loss Decreases, Beats Estimates | WASHINGTON (dpa-AFX) - Palatin Technologies Inc. (PTN) revealed Loss for second quarter that decreased from the same period last year and beat the Street estimates.The company's earnings came... ► Artikel lesen | |
| BIOXXMED | 0,832 | 0,00 % | EQS-Adhoc: bioXXmed AG: bioXXmed beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts | EQS-Ad-hoc: bioXXmed AG / Schlagwort(e): Sonstiges
bioXXmed AG beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts
21.02.2025 / 20:29 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| ORGANOVO | 0,688 | +1,47 % | Organovo, Inc.: Organovo's FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company | SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches... ► Artikel lesen | |
| OCUGEN | 0,581 | +0,17 % | Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease | MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,878 | -0,59 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile | Sustained benefit demonstrated with elevated expression of alpha-galactosidase A (a-Gal A) activity maintained for nearly four years for the longest treated patient as of the data cutoff date Positive... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -1,33 % | Sirona Biochem präsentiert TFC-1326 in wegweisendem Bericht von Stonegate Healthcare | 15. Januar 2025 - Vancouver, British Columbia / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB:
ZSB) (OTC: SRBCF) freut sich bekannt zu geben, dass sein innovativer Anti-Aging-Wirkstoff TFC-1326... ► Artikel lesen | |
| BIO-GATE | 0,755 | -3,82 % | EQS-News: Bio-Gate AG: Medizinisches CBD-Muskelpflege-Gel von Bio-Gate erhält in klinischer Studie Testergebnis "sehr gut" | EQS-News: Bio-Gate AG
/ Schlagwort(e): Studienergebnisse/Sonstiges
Bio-Gate AG: Medizinisches CBD-Muskelpflege-Gel von Bio-Gate erhält in klinischer Studie Testergebnis "sehr... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,796 | -5,24 % | Defence Therapeutics Inc.: Defence Closes Second Tranche of Fully Subscribed Financing Totaling $4.2 Million | Montreal, Quebec--(Newsfile Corp. - January 31, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing... ► Artikel lesen | |
| VAXART | 0,460 | +2,04 % | Vaxart, Inc.: Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial | Independent Data Safety Monitoring Board (DSMB) recommends study to proceed without modifications based on initial safety assessment of 400 participant 30-day data The company plans to progress the... ► Artikel lesen | |
| TEMPUS AI | 50,94 | 0,00 % | Palantir | Hims | Tempus AI - DeepSeek kurbelt Chipnachfrage von Nvidia an! | Markus Weingran - Mein Tipp: SMARTBROKER+: https://broker-tipp.de/ (Werbung) Willkommen bei der Börsenlounge mit Markus Weingran. Die Themen heute: Palantir | Hims | Tempus AI - DeepSeek kurbelt Chipnachfrage... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 0,056 | +1,46 % | Burcon NutraScience Corporation: Burcon Announces Details of $9.43 Million Rights Offering | Vancouver, British Columbia--(Newsfile Corp. - February 18, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development... ► Artikel lesen | |
| AFFIMED | 0,900 | -4,26 % | XFRA DIVERSE INSTRUMENTE: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCASTOR MARITIME... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 0,266 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring | Evaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data and a substantial market opportunity Focusing on advancing radiotherapeutic assets including... ► Artikel lesen | |
| IMMUNIC | 1,077 | -3,15 % | EQS-News: Immunic AG: Immunic to Participate in Scientific and Investor Conferences in March | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Scientific and Investor Conferences in March
03.03.2025 / 12:30 CET/CEST
The issuer is solely... ► Artikel lesen |
Das Unternehmen ELEVATION ONCOLOGY INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,490 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELEVATION ONCOLOGY INC finden Sie auf Wallstreet Online.
